MXPA03010321A - Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. - Google Patents

Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.

Info

Publication number
MXPA03010321A
MXPA03010321A MXPA03010321A MXPA03010321A MXPA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A
Authority
MX
Mexico
Prior art keywords
receptor
lower alkyl
neurikinin
undecan
diaza
Prior art date
Application number
MXPA03010321A
Other languages
English (en)
Spanish (es)
Inventor
Cai Hai-Ying
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03010321A publication Critical patent/MXPA03010321A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MXPA03010321A 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. MXPA03010321A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
PCT/EP2002/004935 WO2002092604A1 (en) 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Publications (1)

Publication Number Publication Date
MXPA03010321A true MXPA03010321A (es) 2004-02-17

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010321A MXPA03010321A (es) 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.

Country Status (17)

Country Link
US (1) US6599900B2 (enExample)
EP (1) EP1390372B1 (enExample)
JP (1) JP4056887B2 (enExample)
KR (1) KR100618063B1 (enExample)
CN (1) CN1264847C (enExample)
AR (1) AR033631A1 (enExample)
AT (1) ATE401333T1 (enExample)
AU (1) AU2002342238B2 (enExample)
BR (1) BR0209604A (enExample)
CA (1) CA2447329C (enExample)
DE (1) DE60227657D1 (enExample)
DK (1) DK1390372T3 (enExample)
ES (1) ES2310206T3 (enExample)
MX (1) MXPA03010321A (enExample)
PT (1) PT1390372E (enExample)
WO (1) WO2002092604A1 (enExample)
ZA (1) ZA200308535B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554671A1 (en) 2004-02-10 2005-08-18 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
EA012421B1 (ru) * 2005-03-03 2009-10-30 Янссен Фармацевтика Н. В. Замещённые производные оксадиазаспиро[5.5]ундеканона и их применение в качестве антагонистов нейрокинина
CN101137657B (zh) 2005-03-08 2011-02-02 詹森药业有限公司 作为神经激肽(nk1)拮抗剂的二氮杂-螺-[4.4]-壬烷衍生物
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
BRPI0809646A2 (pt) 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
CN107849017B (zh) 2015-07-31 2021-03-30 辉瑞公司 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
AU2018208846A1 (en) 2017-01-20 2019-07-25 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
WO2018134698A1 (en) 2017-01-23 2018-07-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation

Also Published As

Publication number Publication date
PT1390372E (pt) 2008-08-25
CN1507449A (zh) 2004-06-23
CA2447329C (en) 2009-07-28
DE60227657D1 (de) 2008-08-28
CA2447329A1 (en) 2002-11-21
CN1264847C (zh) 2006-07-19
JP2004534758A (ja) 2004-11-18
EP1390372B1 (en) 2008-07-16
BR0209604A (pt) 2004-03-23
ES2310206T3 (es) 2009-01-01
AR033631A1 (es) 2003-12-26
US20030004163A1 (en) 2003-01-02
WO2002092604A1 (en) 2002-11-21
ATE401333T1 (de) 2008-08-15
US6599900B2 (en) 2003-07-29
KR20030094405A (ko) 2003-12-11
DK1390372T3 (da) 2008-09-15
KR100618063B1 (ko) 2006-08-30
ZA200308535B (en) 2005-01-31
JP4056887B2 (ja) 2008-03-05
EP1390372A1 (en) 2004-02-25
AU2002342238B2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
MY147451A (en) 4-phenyl-pyridine derivatives and their use as nk-1 receptor antagonists
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
IL184687A0 (en) Pharmaceutical compositions containing 1,2-dihydropyridin-2-one derivatives
CA2286723A1 (en) Tricyclic compounds
PL367105A1 (en) Quinoline derivative having azolyl group and quinazoline derivative
MXPA03010321A (es) Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
AU2002213421A1 (en) Condensed pyridoindole derivatives
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
JO2321B1 (en) 4-phenyl-pyridine derivatives
IL159880A0 (en) Arylsulfonyl derivatives with 5-ht6 receptor affinity
ATE154021T1 (de) N-cyclohexyl benzamide derivate, ihre herstellungen und therapeutischen anwendungen
DE60208178D1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
AU1367497A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of prostatic carcinoma
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
YU86603A (sh) Novi derivati piperidinkarboksamida, postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže
CA2346896A1 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
NO973340L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme
NO973242L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti
CA2192596A1 (en) 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety
DE69002217D1 (de) Dibenzodioxazecin- und dibenzodioxaazacycloundecin-derivate.

Legal Events

Date Code Title Description
FG Grant or registration